<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320710</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446E2352</org_study_id>
    <nct_id>NCT00320710</nct_id>
  </id_info>
  <brief_title>Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer</brief_title>
  <official_title>A Prospective, Randomized, Double-blind, Stratified, Multi-center, 2-arm Trial of the Continued Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in in the 2nd Year of Treatment in Patients With Documented Bone Metastases From Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial in breast cancer patients with bone metastases pretreated for approximately 1
      year with a standard zoledronic acid regimen. Looking at the continued effectiveness and
      safety of giving zoledronic acid every 4 weeks versus every 12 weeks given over 1 year. This
      study is prospective, double-blind, stratified, multi-center, and two-arm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Who Experienced at Least One Skeletal Related Event (SRE)</measure>
    <time_frame>52 weeks</time_frame>
    <description>An SRE was defined as a pathologic fracture (vertebral and non-vertebral), spinal cord compression, radiation to bone or surgery to bone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First SRE</measure>
    <time_frame>52 weeks</time_frame>
    <description>An SRE was defined as a pathologic bone fracture (vertebral and non-vertebral), spinal cord compression, radiation to bone, or surgery to bone. The time to first individual SRE was defined as the date of randomization to the date of first occurrence of any SRE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Individual Type of SRE</measure>
    <time_frame>52 weeks</time_frame>
    <description>Types of SREs analyzed were pathologic fractures (vertebral and non-vertebral), spinal cord compression, radiation to bone and surgery to bone. The time to first indvidual SRE was defined as the date of randomization to the date of the first occurrence of any individual SRE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Composite Brief Pain Inventory (BPI) Score</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>Participants completed a BPI short form which is a 9 item self-administered questionnaire used to evaluate the severity of a participant's pain and the impact of this pain on the participant's daily functioning. The participant rates his or her worst, least, average, and current pain intensity, lists current treatments and perceived effectiveness, and rates the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life on a 10 point scale. The BPI composite score, which was calculated as the average of items 3, 4, 5 and 6 (worst pain, least pain, average pain and pain right now), ranged from 0 (best possible outcome, no pain) to 10 (worst possible outcome, pain as bad as you can imagine). A positive change from baseline indicates worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Analgesic Score</measure>
    <time_frame>baseline, 52 weeks</time_frame>
    <description>The analgesic score indicates the types of pain medication used. The scores range as follows: 0 = none medication; 1 = minor analgesics (aspirin, NSAID, acetaminophen, propoxyphene, etc.); 2 = Tranquilizers, antidepressants, muscle relaxants, and steroids; 3 = Mild narcotics (oxycodone, meperidine, codeine, etc.); and 4 = Strong narcotics (morphine, hydromorphone, etc.). A positive change from baseline indicates worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary N-telopeptide / Creatinine Ratio</measure>
    <time_frame>baseline, 48 weeks</time_frame>
    <description>Urine samples were collected to obtain n-telopeptide and creatinine values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Bone Specific Alkaline Phosphatase</measure>
    <time_frame>baseline, 48 weeks</time_frame>
    <description>Serum samples were collected to obtain bone specific alkaline phosphatase values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal Morbidity Rate</measure>
    <time_frame>52 weeks</time_frame>
    <description>An SMR for a patient was defined as the &quot;number of occurrences&quot; of any (or a particular) SRE allowing for only 1 event in any 3-week interval, divided by the &quot;time at risk&quot; in years. The &quot;number of occurrences&quot; and the &quot;time at risk&quot; were counts of SRE and the time from the randomization date. Counting began from randomization in the way that every counted event was followed by a 20-day period during which no SRE was counted, nor was the time counted as &quot;at risk&quot;. For example, if a patient had 1 SRE during the study, the &quot;time at risk&quot; was calculated as the total number of days in the study minus the 20-day follow-up period for that SRE. If a patient had no SRE events, the entire study period was counted as &quot;time at risk&quot;. This SMR calculation method had the advantage of avoiding multiple counts of possibly interdependent SREs (e.g. having 1 fracture increases the probability of having a subsequent SRE).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">416</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Zoledronic acid every (q) 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoledronic acid q 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo / zoledronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were swithced to the zoledronic acid q 4 weeks according to a study amendment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>4mg IV</description>
    <arm_group_label>Zoledronic acid every (q) 4 weeks</arm_group_label>
    <arm_group_label>Zoledronic acid q 12 weeks</arm_group_label>
    <arm_group_label>Placebo / zoledronic acid</arm_group_label>
    <other_name>Zoledronate</other_name>
    <other_name>ZOL446</other_name>
    <other_name>Zometa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to zoledronic acid</description>
    <arm_group_label>Zoledronic acid q 12 weeks</arm_group_label>
    <arm_group_label>Placebo / zoledronic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Female patients ≥ 18 years of age. Confirmed breast cancer with bone metastasis. Pretreated
        with Zometa®, or Aredia (pamidronate) or all sequential regimens of both, for a minimum of
        9 doses;

        Exclusion Criteria:

        Abnormal kidney function determined by serum creatinine levels. Current active dental
        problems including: ongoing infection of the teeth or jawbone; current exposed bone in the
        mouth; and current or prior diagnosis of osteonecrosis of the jaw.

        Recent (within 8 weeks) or planned dental or jaw surgery (e.g., extraction, implants).

        Diagnosis of metabolic bone disease other than osteoporosis (e.g., Paget's disease of
        bone).

        Known hypersensitivity to Zometa. Treatment with other investigational drugs within 30 days
        prior to randomization.

        Other protocol-defined exclusion criteria may have applied.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Alaska Medical Center Cancer Research</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heritage Physicians Group Oncology</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Chest Care</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center, Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bay Oncology Hematology Partners</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Cancer Research</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Coast Hem/Onc</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group</name>
      <address>
        <city>La Verne</city>
        <state>California</state>
        <zip>91750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenmar Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Valley Hematology/Oncology Providence Holy Cross Medical</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Care Associates</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura County Hematology and Oncology</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Dr. Swarna Chanduri, MD</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Access Clinical Research</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer and Blood of the Desert</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health Medical Center CACZ885M2301</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204-4507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology &amp; Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University/Lombardi Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasco Hernando Oncology</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Office of Dr. Elizabeth Tan-Chiu, MD PA</name>
      <address>
        <city>Planatation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Hematology-Oncology</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Northwestern Healthcare Medical Group</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Cancer Center</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Cancer Research Group</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Physicians &amp; Surgeons Clinic</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates Clinic, PC</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Health Care</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology-Oncology Associates LLP</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Oncology Clinic</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Witchita</city>
        <state>Kansas</state>
        <zip>67214-3728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Lung Clinic &amp; Kentucky Sleep Clinic</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexington Oncology Associates</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Center for Cancer Care</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Oncology Associates Ltd.</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenbaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Agnes Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Harry and Jeanette Weinberg Cancer Institute at Franklin</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer &amp; Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederick Memorial Hospital</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas Holy Family Hospital</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Clinical Trials Office</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital Oncology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Care Associates, PLLC</name>
      <address>
        <city>St. Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital and Health Network</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Clinical Trial Services</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Minnesota Cancer Center 420 Delaware St.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubert H. Humphrey Cancer Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Oncology Associates</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capitol Comprehensive Cancer Care Clinic</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer Care and Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Hematology-Oncology PC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Centers 2851 North Tenaya Way</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Hematologic Disease</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Hematology Oncology Associates</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Oncology Associates</name>
      <address>
        <city>Armonk</city>
        <state>New York</state>
        <zip>10504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arena Oncology Associates, PC</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benedictine Hospital</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jmaes P. Wilmot Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Regional Medical Cancer Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Oncology Associates Suite 250</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barberton Citizens Hospital</name>
      <address>
        <city>Barberton</city>
        <state>Ohio</state>
        <zip>44203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Cancer Specialists</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Consultants Inc.</name>
      <address>
        <city>West Worthington</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trilogy Cancer Care</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Hospital - Pharmacy</name>
      <address>
        <city>Coos Bay</city>
        <state>Oregon</state>
        <zip>97420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Corvallis Clinic, P.C.</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster Cancer Center</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U of Pittsburgh Cancer Institute Magee-Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guthrie Cancer Center</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mainline Oncology Hematology Assoc.</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. Francisco Gonzalez, MD., FACP</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santee Hematology/Oncology</name>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas 1155 Herman Pressler Street</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Everett Medical Clinic</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockwood Clinic Rockwood Clinic, PS</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>http://www.breastcancerresearchstudy.com</url>
    <description>Breast Cancer</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2006</study_first_submitted>
  <study_first_submitted_qc>April 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <results_first_submitted>July 8, 2014</results_first_submitted>
  <results_first_submitted_qc>July 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2014</results_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>zoledronic acid</keyword>
  <keyword>bone metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The initial study design contained 3 arms: zoledronic acid q4 weeks, zoledronic acid q12 weeks and placebo q4 weeks. Due to a study amendment, the placebo arm was discontinued and participants in this treatment group were switched to the zoledronic acid q4 week group. These participants were not included in the efficacy analysis.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Zoledronic Acid Every (q) 4 Weeks</title>
          <description>Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Zoledronic Acid q 12 Weeks</title>
          <description>Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.</description>
        </group>
        <group group_id="P3">
          <title>Placebo / Zoledronic Acid</title>
          <description>Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were later switched to the zoledronic acid q 4 weeks according to a study amendment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated (Safety Set)</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="127"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zoledronic Acid Every (q) 4 Weeks</title>
          <description>Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Zoledronic Acid q 12 Weeks</title>
          <description>Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.</description>
        </group>
        <group group_id="B3">
          <title>Placebo / Zoledronic Acid</title>
          <description>Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were later switched to the zoledronic acid q 4 weeks according to a study amendment.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="203"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="416"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="11.10"/>
                    <measurement group_id="B2" value="58.6" spread="11.15"/>
                    <measurement group_id="B3" value="60.8" spread="12.19"/>
                    <measurement group_id="B4" value="58.9" spread="11.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>All participants were female.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Who Experienced at Least One Skeletal Related Event (SRE)</title>
        <description>An SRE was defined as a pathologic fracture (vertebral and non-vertebral), spinal cord compression, radiation to bone or surgery to bone.</description>
        <time_frame>52 weeks</time_frame>
        <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every (q) 4 Weeks</title>
            <description>Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid q 12 Weeks</title>
            <description>Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Experienced at Least One Skeletal Related Event (SRE)</title>
          <description>An SRE was defined as a pathologic fracture (vertebral and non-vertebral), spinal cord compression, radiation to bone or surgery to bone.</description>
          <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First SRE</title>
        <description>An SRE was defined as a pathologic bone fracture (vertebral and non-vertebral), spinal cord compression, radiation to bone, or surgery to bone. The time to first individual SRE was defined as the date of randomization to the date of first occurrence of any SRE.</description>
        <time_frame>52 weeks</time_frame>
        <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every (q) 4 Weeks</title>
            <description>Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid q 12 Weeks</title>
            <description>Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First SRE</title>
          <description>An SRE was defined as a pathologic bone fracture (vertebral and non-vertebral), spinal cord compression, radiation to bone, or surgery to bone. The time to first individual SRE was defined as the date of randomization to the date of first occurrence of any SRE.</description>
          <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not estimable because there were too few events to calculate the median.</measurement>
                    <measurement group_id="O2" value="NA">The median was not estimable because there were too few events to calculate the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Individual Type of SRE</title>
        <description>Types of SREs analyzed were pathologic fractures (vertebral and non-vertebral), spinal cord compression, radiation to bone and surgery to bone. The time to first indvidual SRE was defined as the date of randomization to the date of the first occurrence of any individual SRE.</description>
        <time_frame>52 weeks</time_frame>
        <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every (q) 4 Weeks</title>
            <description>Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid q 12 Weeks</title>
            <description>Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Individual Type of SRE</title>
          <description>Types of SREs analyzed were pathologic fractures (vertebral and non-vertebral), spinal cord compression, radiation to bone and surgery to bone. The time to first indvidual SRE was defined as the date of randomization to the date of the first occurrence of any individual SRE.</description>
          <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vertebral pathologic fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not estimable because too few events occurred to calculate the median.</measurement>
                    <measurement group_id="O2" value="NA">The median was not estimable because too few events occurred to calculate the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-vertebral pathologic fractures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not estimable because too few events occurred to calculate the median.</measurement>
                    <measurement group_id="O2" value="NA">The median was not estimable because too few events occurred to calculate the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal cord compression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not estimable because too few events occurred to calculate the median.</measurement>
                    <measurement group_id="O2" value="NA">The median was not estimable because too few events occurred to calculate the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiation to bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not estimable because too few events occurred to calculate the median.</measurement>
                    <measurement group_id="O2" value="NA">The median was not estimable because too few events occurred to calculate the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery to bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median was not estimable because too few events occurred to calculate the median.</measurement>
                    <measurement group_id="O2" value="NA">The median was not estimable because too few events occurred to calculate the median.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Composite Brief Pain Inventory (BPI) Score</title>
        <description>Participants completed a BPI short form which is a 9 item self-administered questionnaire used to evaluate the severity of a participant's pain and the impact of this pain on the participant's daily functioning. The participant rates his or her worst, least, average, and current pain intensity, lists current treatments and perceived effectiveness, and rates the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life on a 10 point scale. The BPI composite score, which was calculated as the average of items 3, 4, 5 and 6 (worst pain, least pain, average pain and pain right now), ranged from 0 (best possible outcome, no pain) to 10 (worst possible outcome, pain as bad as you can imagine). A positive change from baseline indicates worsening.</description>
        <time_frame>baseline, 52 weeks</time_frame>
        <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups and had both baseline and week 52 values.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every (q) 4 Weeks</title>
            <description>Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid q 12 Weeks</title>
            <description>Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Composite Brief Pain Inventory (BPI) Score</title>
          <description>Participants completed a BPI short form which is a 9 item self-administered questionnaire used to evaluate the severity of a participant's pain and the impact of this pain on the participant's daily functioning. The participant rates his or her worst, least, average, and current pain intensity, lists current treatments and perceived effectiveness, and rates the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life on a 10 point scale. The BPI composite score, which was calculated as the average of items 3, 4, 5 and 6 (worst pain, least pain, average pain and pain right now), ranged from 0 (best possible outcome, no pain) to 10 (worst possible outcome, pain as bad as you can imagine). A positive change from baseline indicates worsening.</description>
          <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups and had both baseline and week 52 values.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="1.976"/>
                    <measurement group_id="O2" value="0.31" spread="2.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Analgesic Score</title>
        <description>The analgesic score indicates the types of pain medication used. The scores range as follows: 0 = none medication; 1 = minor analgesics (aspirin, NSAID, acetaminophen, propoxyphene, etc.); 2 = Tranquilizers, antidepressants, muscle relaxants, and steroids; 3 = Mild narcotics (oxycodone, meperidine, codeine, etc.); and 4 = Strong narcotics (morphine, hydromorphone, etc.). A positive change from baseline indicates worsening.</description>
        <time_frame>baseline, 52 weeks</time_frame>
        <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups and had both baseline and week 52 values.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every (q) 4 Weeks</title>
            <description>Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid q 12 Weeks</title>
            <description>Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Analgesic Score</title>
          <description>The analgesic score indicates the types of pain medication used. The scores range as follows: 0 = none medication; 1 = minor analgesics (aspirin, NSAID, acetaminophen, propoxyphene, etc.); 2 = Tranquilizers, antidepressants, muscle relaxants, and steroids; 3 = Mild narcotics (oxycodone, meperidine, codeine, etc.); and 4 = Strong narcotics (morphine, hydromorphone, etc.). A positive change from baseline indicates worsening.</description>
          <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups and had both baseline and week 52 values.</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.28"/>
                    <measurement group_id="O2" value="0.5" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinary N-telopeptide / Creatinine Ratio</title>
        <description>Urine samples were collected to obtain n-telopeptide and creatinine values.</description>
        <time_frame>baseline, 48 weeks</time_frame>
        <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups and had both baseline and week 48 values.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every (q) 4 Weeks</title>
            <description>Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid q 12 Weeks</title>
            <description>Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinary N-telopeptide / Creatinine Ratio</title>
          <description>Urine samples were collected to obtain n-telopeptide and creatinine values.</description>
          <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups and had both baseline and week 48 values.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.612" spread="40.4073"/>
                    <measurement group_id="O2" value="14.697" spread="57.7315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Bone Specific Alkaline Phosphatase</title>
        <description>Serum samples were collected to obtain bone specific alkaline phosphatase values.</description>
        <time_frame>baseline, 48 weeks</time_frame>
        <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups and had both baseline and week 48 values.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every (q) 4 Weeks</title>
            <description>Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid q 12 Weeks</title>
            <description>Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Bone Specific Alkaline Phosphatase</title>
          <description>Serum samples were collected to obtain bone specific alkaline phosphatase values.</description>
          <population>The population included participants who were in the zoledronic acid q4 weeks and zoledronic acid q12 weeks treatment groups and had both baseline and week 48 values.</population>
          <units>mcg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.797" spread="27.8800"/>
                    <measurement group_id="O2" value="4.514" spread="12.4509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skeletal Morbidity Rate</title>
        <description>An SMR for a patient was defined as the “number of occurrences” of any (or a particular) SRE allowing for only 1 event in any 3-week interval, divided by the “time at risk” in years. The “number of occurrences” and the “time at risk” were counts of SRE and the time from the randomization date. Counting began from randomization in the way that every counted event was followed by a 20-day period during which no SRE was counted, nor was the time counted as “at risk”. For example, if a patient had 1 SRE during the study, the “time at risk” was calculated as the total number of days in the study minus the 20-day follow-up period for that SRE. If a patient had no SRE events, the entire study period was counted as “time at risk”. This SMR calculation method had the advantage of avoiding multiple counts of possibly interdependent SREs (e.g. having 1 fracture increases the probability of having a subsequent SRE).</description>
        <time_frame>52 weeks</time_frame>
        <population>This population included all participants who were in the zoledronic acid q 4 weeks and zoledronic acid q 12 weeks treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid Every (q) 4 Weeks</title>
            <description>Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Zoledronic Acid q 12 Weeks</title>
            <description>Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.</description>
          </group>
        </group_list>
        <measure>
          <title>Skeletal Morbidity Rate</title>
          <description>An SMR for a patient was defined as the “number of occurrences” of any (or a particular) SRE allowing for only 1 event in any 3-week interval, divided by the “time at risk” in years. The “number of occurrences” and the “time at risk” were counts of SRE and the time from the randomization date. Counting began from randomization in the way that every counted event was followed by a 20-day period during which no SRE was counted, nor was the time counted as “at risk”. For example, if a patient had 1 SRE during the study, the “time at risk” was calculated as the total number of days in the study minus the 20-day follow-up period for that SRE. If a patient had no SRE events, the entire study period was counted as “time at risk”. This SMR calculation method had the advantage of avoiding multiple counts of possibly interdependent SREs (e.g. having 1 fracture increases the probability of having a subsequent SRE).</description>
          <population>This population included all participants who were in the zoledronic acid q 4 weeks and zoledronic acid q 12 weeks treatment groups.</population>
          <units>Number of events per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="1.063"/>
                    <measurement group_id="O2" value="0.50" spread="1.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zoledronic Acid Every (q) 4 Weeks</title>
          <description>Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Zoledronic Acid q 12 Weeks</title>
          <description>Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.</description>
        </group>
        <group group_id="E3">
          <title>Placebo / Zoledronic Acid</title>
          <description>Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were later switched to the zoledronic acid q 4 weeks according to a study amendment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia of malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Perforated ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vasogenic cerebral oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Serum ferritin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

